论文部分内容阅读
目的:探讨将尤瑞克林应用到进展性脑梗死治疗中的效果及对血清超敏C-反应蛋白(hs-CRP)的影响。方法:选择2015年1月至2016年1月中山大学附属第一医院惠亚医院接收治疗的进展性脑梗死患者60例,按临床随机数表法分为观察与对照两组,各30例,给予对照组常规性治疗,观察组在对照组基础上给予尤瑞克林治疗,分析两组疗效及hs-CRP变化情况。结果:观察组治疗总有效率为96.7%,明显比对照组的76.7%高,观察组hs-CRP下降程度明显比对照组优越,差异具有统计学意义(P<0.05),两组均未出现严重不良反应。结论:将尤瑞克林应用进展性脑梗死治疗,可使hs-CRP含量明显下降,对患者神经功能缺损进行改善,进而提高临床效果,使患者早日康复。
Objective: To investigate the effect of applying uracil to the treatment of progressive cerebral infarction and its effect on serum hs-CRP. Methods: Sixty patients with progressive cerebral infarction admitted to the First Affiliated Hospital of Sun Yat-sen University from January 2015 to January 2016 were randomly divided into observation and control groups, 30 cases in each group, The control group was given routine treatment. The observation group was treated with urelin based on the control group. The curative effect and changes of hs-CRP in both groups were analyzed. Results: The total effective rate of observation group was 96.7%, significantly higher than that of 76.7% in control group. The decrease of hs-CRP in observation group was significantly superior to that of control group (P <0.05), and no significant difference was found between the two groups Serious adverse reactions. Conclusion: The application of ureclin in patients with advanced cerebral infarction can significantly reduce the content of hs-CRP, and improve the neurological deficit in patients, thereby improving the clinical effect and enabling patients to recover as soon as possible.